Buprenorphine 101: The Basics of Initiating and Managing Opioid Use Disorder Treatment with Medication (For BORIM)
PLEASE NOTE: the training video is best viewed in Microsoft Edge or Google Chrome
This course will provide a brief introduction to the use of buprenorphine for the treatment of opioid use disorder. It will cover the basics needed to be able to effectively identify when buprenorphine treatment is appropriate, to initiate, monitor and maintain treatment.
This activity is intended for: Prescribers (physicians, NPs, and PAs from primary care, emergency medicine, hospitalists service, OB/GYN and others) interested in using buprenorphine to treat opioid use disorder.
At the conclusion of this activity participants should be able to:
- Describe why treating opioid use disorder is an important, feasible, and satisfying clinical skill for all providers to easily master;
- Detail how to diagnose and treat opioid use disorder with buprenorphine in usual clinical practice;
- Dispel common myths about buprenorphine prescribing and review practical tips for getting started.
Mass General Brigham Quality and Patient Experience’s Substance Use Disorders Initiative
|60 min||Opioid Addiction – A Public Health Crisis||Sarah E. Wakeman, MD, FASAM|
|The Case for Buprenorphine||Sarah E. Wakeman, MD, FASAM|
|Dispelling the Myths Around Treating Opioid Use Disorder (OUD)||Claudia P. Rodriguez, MD|
|Opportunities for and Access to OUD Treatment||Sarah E. Wakeman, MD, FASAM|
Treating OUD with Buprenorphine:
|Sarah E. Wakeman, MD, FASAM|
Sarah E. Wakeman, MD, FASAM - Course Director
Dr. Wakeman is an addiction medicine specialist at Mass General and a national thought leader in treatment for substance use disorders. As the medical director for the hospital's Substance Use Disorders Initiative, she is committed to changing how addiction is understood by the public and how it is treated at Mass General.
In addition to serving as the medical director of the Substance Use Disorders Initiative at Mass General, Dr. Wakeman leads the Addiction Consult Team, co-chairs the Opioid Task Force and is the medical director for Substance Use Disorder for Mass General Brigham’s Quality and Patient Experience area. She is also an associate professor in medicine at Harvard Medical School.
Dr. Wakeman’s clinical interest and expertise is in the care of patients with addiction within general medical settings. Clinically, she provides primary care and office-based addiction care, as well as inpatient specialty consultation for addiction. She teaches locally, regionally and nationally about addiction and has led workshops and delivered symposia at national conferences. She was appointed by Governor Charlie Baker to serve on his opioid addiction working group and previously served as secretary for the Massachusetts Society of Addiction Medicine and chair of the group’s policy committee.
She also conducts research devoted to evaluating the implementation of substance use disorder care in general medical settings, opioid use disorder treatment effectiveness, and physician preparedness and attitudes related to addiction.
Claudia Rodriguez, MD
Dr. Rodriguez is the medical director of addiction services and is the chair of the Brigham Comprehensive Opioid Response and Education Committee (BCORE) services at the Brigham and Women’s Faulkner Hospital (BWFH). Dr. Rodriguez is a clinical leader in expanding addiction treatment across clinical service levels within the hospital. She is a sought out educator, and has presented at local, regional, and national levels, with a goal in enhancing knowledge of SUD treatment and challenging stigma against addiction.
Disclosure Summary of Relevant Financial Relationships
Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose
primary business is producing, marketing, selling, re-selling, or distributing healthcare products
used by or on patients. Examples of such organizations include:
- Advertising, marketing, or communication firms whose clients are ineligible companies
- Bio-medical startups that have begun a governmental regulatory approval process
- Compounding pharmacies that manufacture proprietary compounds
- Device manufacturers or distributors
- Diagnostic labs that sell proprietary products
- Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
- Manufacturers of health-related wearable products
- Pharmaceutical companies or distributors
- Pharmacy benefit managers
- Reagent manufacturers or sellers
For more information: https://accme.org/faq/what-accmes-definition-ineligible-company
Mass General Brigham has implemented a process to mitigate relevant financial relationships for this continuing education (CE)
activity to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public.
The following planners have reported no relevant financial relationship with an ineligible company:
Aleta D. Carroll, LMHC
Daniel Kobrin, MEd
Sarah E. Wakeman, MD, FASAM
The following speakers have reported no relevant financial relationships with an ineligible company:
Sarah E. Wakeman, MD, FASAM
Claudia P. Rodriguez, MD
Original Release Date: October 7, 2021
Expiration Date: October 7, 2023
Review Date: July 29, 2022 by Claudia P. Rodriguez, MD
In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Mass General Brigham designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program meets the requirements of the Massachusetts Board of Registration in Nursing at 244 CMR 5.00 for 1.2 contact hours.
- 1.00 AMA PRA Category 1 Credit™
- 1.20 Nursing Contact Hours
- 1.00 Participation